Pierre Fabre Medicament clinical trials

A subsidiary of Pierre Fabre

The registry lists 73 studies whose lead sponsor is Pierre Fabre Medicament. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 73. List all 73 → · All Pierre Fabre studies →

• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyRecruitingNCT03394365Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsRecruitingNCT06043817Phase 1/2

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsRecruitingNCT04913285Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIsRecruitingNCT06567015Phase 1/2

  Sponsor listed in the registry: Pierre Fabre Medicament

• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsRecruitingNCT06669117Phase 1/2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Treatment Patterns of Neratinib in HER2+ EBC in ChinaNot yet recruitingNCT05491057

  Sponsor listed in the registry: Pierre Fabre Medicament

• Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International StudyCompletedNCT07096206

  Sponsor listed in the registry: Pierre Fabre Medicament

• Study on Structum® in Adult Patients With Osteoarthritis (TRUST)CompletedNCT06623773

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruitingNCT04554914Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedNCT03693170Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of TreatmentActive, not recruitingNCT06500494

  Sponsor listed in the registry: Pierre Fabre Medicament

• Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.CompletedNCT05004350Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)CompletedNCT06690489

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma PatientsCompletedNCT04911998

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)CompletedNCT04317599

  Sponsor listed in the registry: Pierre Fabre Medicament

• The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up StudyTerminatedNCT06688370

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibCompletedNCT05599334

  Sponsor listed in the registry: Pierre Fabre Medicament

• A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic HyperplasiaCompletedNCT07144709

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)CompletedNCT05546905

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid TumorsTerminatedNCT03316638Phase 1/2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Bioequivalence Binimetinib 3 x 15 mg and 45 mg FormulationsCompletedNCT05810740Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsCompletedNCT05003622Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast CancerCompletedNCT03887130Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid TumorsTerminatedNCT04564417Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand EczemaWithdrawnNCT05545215

  Sponsor listed in the registry: Pierre Fabre Medicament

• Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Active, not recruitingNCT05270044Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWithdrawnNCT04759846Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical TrialCompletedNCT04875026Phase 4

  Sponsor listed in the registry: Pierre Fabre Medicament

• Trial of Vinflunine Plus Capecitabine in Advanced Breast CancerCompletedNCT01095003Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg FormulationsStatus unknownNCT05103891Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerCompletedNCT01091168Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast CancerTerminatedNCT02054338Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Efficacy and Safety Study of F373280CompletedNCT01831856Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT01953003Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck CancerCompletedNCT02347332Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKSWithdrawnNCT02907320Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) StudyCompletedNCT01948856Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• F17464 in Acute Schizophrenia TrialCompletedNCT02151656Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous OedemaCompletedNCT01402921Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance ImagingCompletedNCT02266966Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung CancerCompletedNCT00683514Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament

• Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency AnaemiaTerminatedNCT02518568Phase 1

  Sponsor listed in the registry: Pierre Fabre Medicament

• PERmixon® in LUTS Evaluation Study (PERLES)CompletedNCT02121613Phase 4

  Sponsor listed in the registry: Pierre Fabre Medicament

• Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar ExtractionCompletedNCT02382809Phase 4

  Sponsor listed in the registry: Pierre Fabre Medicament

• JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus CarboplatinCompletedNCT01599013Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Assessment of V0018 2.5 mg Effect on CravingCompletedNCT02357888Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.CompletedNCT02045199Not applicable

  Sponsor listed in the registry: Pierre Fabre Medicament

• Assessment of V0018 1.5 mg Effect on CravingCompletedNCT02359201Phase 2

  Sponsor listed in the registry: Pierre Fabre Medicament

• Effect of F2695 on Functional Recovery After Ischemic StrokeCompletedNCT01639014Phase 3

  Sponsor listed in the registry: Pierre Fabre Medicament